Clinical efficacy, safety, and subjective experience based on ePRO in HIV-infected individuals administered bicetivir, entatabine, and propofol tenofovir in southwest China

Author:

Kong Linghong1,Xie Xiaoxin2,Fu Yanhua2,Gan Lin2,Yang Xiaoyan1,Ma Shujing1,Long Hai2

Affiliation:

1. School of Public Health, the Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Medical University, Guiyang, Guizhou, China

2. Department of Infection, Guiyang Public Health Clinical Center, Guiyang, Guizhou, China

Abstract

Abstract Background: Prospective studies examining long-term therapeutic outcomes of the BIC+FTC+TAF regimen in human immunodeficiency virus (HIV) infection remain limited. This study assessed the actual efficacy and safety of BIC+FTC+TAF in HIV-infected individuals in southwest China. Methods: This was a single-center, prospective study enrolling treatment-naïve (n=32) and treatment-experienced (n=177) HIV-infected patients administered BIC+FTC+TAF treatment between March 2022 and August 2022. The data were collected until February 28, 2023. Virological reactions and adverse events to the treatment were recorded, and patient subjective feelings in the form of ePRO were collected. The primary endpoint was the rate of patients with HIV viral load <50 copies/mL at week 24. Results: At week 24, 87.5% and 95.5% of treatment-naïve and treatment-experienced HIV patients had a viral load <50 copies/mL, respectively. CD4 cell counts in treatment-naïve and treatment-experienced patients increased significantly by 163.5 cells/μL (P=0.002) and 55.0 cells/μL (P=0.022), respectively. By week 24, no patients had discontinued the BIC+FTC+TAF treatment due to adverse events. Based on ePRO data, treatment-naïve and treatment-experienced patients at week 24 had stable disease symptom burden, quality of life, and depression level after treatment with BIC+FTC+TAF. Conclusion: BIC+FTC+TAF reduces the viral load in treatment-naïve patients with high viral load as well as treatment-experienced patients with residual viremia. The patient's subjective experience was maintained stable after treatment with BIC+FTC+TAF. This study also revealed a very low incidence for BIC+FTC+TAF drug-related side effects.

Publisher

Research Square Platform LLC

Reference23 articles.

1. Treatment Adherence And Persistence Among HIV-1 Patients Newly Starting Treatment;Hines DM;Patient Prefer Adherence,2019

2. Patient-reported Outcome: Comparison between the Domestic and the Global Application Progress;Chengchen L;Chin J Drug Evaluation,2015

3. Application of ePRO assessing efficacy in clinical trials of new drugs;Xiaoxian L;Drug Evaluation Research,2021

4. Jianjun.Li. Chinese guidelines for the prevention and treatment of dyslipidemia in adults (2016 revision);Junren Z;Chin Circulation J,2016

5. Development and validation of a self-completed HIV symptom index;Justice AC;J Clin Epidemiol,2001

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3